Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 12
1952 18
1953 17
1954 18
1955 28
1956 30
1957 20
1958 20
1959 12
1960 15
1961 15
1962 14
1963 3
1965 15
1966 55
1967 68
1968 80
1969 88
1970 65
1971 90
1972 97
1973 97
1974 115
1975 106
1976 122
1977 119
1978 121
1979 135
1980 107
1981 147
1982 135
1983 134
1984 161
1985 208
1986 207
1987 306
1988 267
1989 373
1990 377
1991 407
1992 436
1993 475
1994 446
1995 492
1996 516
1997 499
1998 518
1999 481
2000 498
2001 552
2002 593
2003 703
2004 672
2005 725
2006 742
2007 874
2008 875
2009 930
2010 1049
2011 1161
2012 1201
2013 1207
2014 1350
2015 1368
2016 1305
2017 1313
2018 1278
2019 575
2020 14
Text availability
Article attribute
Article type
Publication date

Search Results

24,947 results
Results by year
Filters applied: . Clear all
Page 1
Acute myeloid leukemia in the elderly: therapeutic options and choice.
Webster JA and Pratz KW. Leuk Lymphoma 2018 - Review. PMID 28573892
Acute myeloid leukemia (AML) therapies are rapidly evolving with novel targeted therapies showing high-level responses in a notoriously difficult to treat group of patients - the elderly and unfit. ...Low-intensity combination therapy response rates appear to be approaching that of induction regimens, and with lower toxicity, low-intensity therapy likely represents the future standard approach in this age group. ...
Acute myeloid leukemia (AML) therapies are rapidly evolving with novel targeted therapies showing high-level responses in a no …
Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Prevention, Detection, and Treatment.
Rautenberg C, et al. Int J Mol Sci 2019 - Review. PMID 30626126 Free PMC article.
Acute myeloid leukemia (AML) is a phenotypically and prognostically heterogeneous hematopoietic stem cell disease that may be cured in eligible patients with intensive chemotherapy and/or allogeneic stem cell transplantation (allo-SCT). ...Furthermore, with the approval of the FMS-like tyrosine kinase 3 (FLT3) inhibitor Midostaurin a first targeted therapy has been introduced into the first-line therapy of younger patients with FLT3-mutated AML and several other small molecules targeting molecular alterations such as isocitrate dehydrogenase (IDH) mutations or the anti-apoptotic b-cell lymphoma 2 (BCL-2) protein are currently under investigation. ...
Acute myeloid leukemia (AML) is a phenotypically and prognostically heterogeneous hematopoietic stem cell disease that may be …
Acute myeloid leukemia: 2016 Update on risk-stratification and management.
Estey E. Am J Hematol 2016 - Review. PMID 27417880 Free article.
Evidence suggest that even patients aged 70 or above benefit from specific AML therapy. The fundamental decision in AML then becomes whether to recommend standard or investigational treatment. ...Hence we review factors that predict treatment related mortality and resistance to therapy, the latter the principal cause of failure even in patients aged 70 or above. ...
Evidence suggest that even patients aged 70 or above benefit from specific AML therapy. The fundamental decision in AML then becomes …
Precision therapy for acute myeloid leukemia.
Yang X and Wang J. J Hematol Oncol 2018 - Review. PMID 29301553 Free PMC article.
Acute myeloid leukemia (AML) is a molecularly and clinically heterogeneous disease. Despite advances in understanding the pathogenesis of AML, the standard therapy remained nearly unchanged over the past three decades. ...Here, we present a mechanism-based review of some promising new drugs with clinical efficacy, focus on targeted drugs that are most potential to pave the road to success, and put forward the major challenges in promoting the precision therapy for AML....
Acute myeloid leukemia (AML) is a molecularly and clinically heterogeneous disease. Despite advances in understanding the path …
An update of current treatments for adult acute myeloid leukemia.
Dombret H and Gardin C. Blood 2016 - Review. PMID 26660429 Free PMC article.
Recent advances in acute myeloid leukemia (AML) biology and its genetic landscape should ultimately lead to more subset-specific AML therapies, ideally tailored to each patient's disease. ...If one excludes acute promyelocytic leukemia, current AML management still relies largely on intensive chemotherapy and allogeneic hematopoietic stem cell transplantation (HSCT), at least in younger patients who can tolerate such intensive treatments. ...
Recent advances in acute myeloid leukemia (AML) biology and its genetic landscape should ultimately lead to more subset-specif …
Definition of Unfit for Standard Acute Myeloid Leukemia Therapy.
Klepin HD. Curr Hematol Malig Rep 2016 - Review. PMID 27681539
Determining who is fit or unfit for standard treatments among older adults with acute myeloid leukemia (AML) remains a challenge. ...
Determining who is fit or unfit for standard treatments among older adults with acute myeloid leukemia (AML) remains a challen …
Initial therapy for acute myeloid leukemia in older patients: principles of care.
Bhatt VR, et al. Leuk Lymphoma 2018 - Review. PMID 28573900
Older patients with acute myeloid leukemia (AML) frequently have significant comorbidities, geriatric syndromes, and high-risk leukemia that make them susceptible to high early mortality, chemotherapy-related toxicities, and poor long-term survival. ...Development of low intensity but effective therapy is a major need. Deeper understanding of the molecular biology of AML has allowed several novel therapies to enter clinical trials in recent years. ...
Older patients with acute myeloid leukemia (AML) frequently have significant comorbidities, geriatric syndromes, and high-risk …
Measurable residual disease testing for personalized treatment of acute myeloid leukemia.
Ehinger M and Pettersson L. APMIS 2019 - Review. PMID 30919505
This review summarizes - with the practicing hematologist in mind - the methods used to determine measurable residual disease (MRD) in everyday practice with some future perspectives, and the current knowledge about the prognostic impact of MRD on outcome in acute myeloid leukemia (AML), excluding acute promyelocytic leukemia. Possible implications for choice of MRD method, timing of MRD monitoring, and guidance of therapy are discussed in general and in some detail for certain types of leukemia with specific molecular markers to monitor, including core binding factor (CBF)-leukemias and NPM1-mutated leukemias....
This review summarizes - with the practicing hematologist in mind - the methods used to determine measurable residual disease (MRD) in every …
Treatment of Elderly Patients With Acute Myeloid Leukemia.
Thomas X and Le Jeune C. Curr Treat Options Oncol 2017 - Review. PMID 28144802
There is no standard of care for older patients with acute myeloid leukemia (AML) unfit for intensive chemotherapy. AML in older patients remains an area of significant unmet need necessitating novel therapeutic strategies. ...Open new questions concern the necessity of an individualized therapy that may take into account not only an increase in survival but also the maintenance or improvement in terms of quality of life, the management of symptoms, and a maximization of time outside of hospital care. ...
There is no standard of care for older patients with acute myeloid leukemia (AML) unfit for intensive chemotherapy. AML in old …
Acute myeloid leukemia: advancing clinical trials and promising therapeutics.
Daver N, et al. Expert Rev Hematol 2016 - Review. PMID 26910051 Free PMC article.
Recent progress in understanding the biology of acute myeloid leukemia (AML) and the identification of targetable driver mutations, leukemia specific antigens and signal transduction pathways has ushered in a new era of therapy. In many circumstances the response rates with such targeted or antibody-based therapies are superior to those achieved with standard therapy and with decreased toxicity. ...
Recent progress in understanding the biology of acute myeloid leukemia (AML) and the identification of targetable driver mutat …
24,947 results
Jump to page
Feedback